9.89
-0.29 (-2.85%)
| Penutupan Terdahulu | 10.18 |
| Buka | 10.04 |
| Jumlah Dagangan | 330,013 |
| Purata Dagangan (3B) | 5,124,861 |
| Modal Pasaran | 775,804,608 |
| Harga / Buku (P/B) | 3.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -3.07 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.32% |
| Nisbah Semasa (MRQ) | 7.95 |
| Aliran Tunai Operasi (OCF TTM) | -192.25 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -110.31 M |
| Pulangan Atas Aset (ROA TTM) | -31.26% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Replimune Group, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.60 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.51% |
| % Dimiliki oleh Institusi | 107.50% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (Wedbush, 82.00%) | Beli |
| Median | 12.00 (21.34%) | |
| Rendah | 11.00 (BMO Capital, 11.22%) | Pegang |
| 11.00 (JP Morgan, 11.22%) | Pegang | |
| Purata | 13.00 (31.45%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 9.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BMO Capital | 03 Nov 2025 | 11.00 (11.22%) | Pegang | 9.31 |
| HC Wainwright & Co. | 27 Oct 2025 | 12.00 (21.33%) | Beli | 9.33 |
| JP Morgan | 20 Oct 2025 | 11.00 (11.22%) | Pegang | 8.95 |
| Leerink Partners | 20 Oct 2025 | 13.00 (31.45%) | Beli | 8.95 |
| Wedbush | 20 Oct 2025 | 18.00 (82.00%) | Beli | 8.95 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| DHINGRA KAPIL | - | 10.30 | -3,169 | -32,641 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,169 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -32,641 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 10.30 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| DHINGRA KAPIL | Pengarah | 09 Dec 2025 | Jual (-) | 3,169 | 10.30 | 32,641 |
| DHINGRA KAPIL | Pengarah | 09 Dec 2025 | Pelaksanaan pilihan | 3,169 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |